Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of P-Butylaminobenzoyldiethylaminoethyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.77 |
| ▸ | SCN1A known ✓ | P35498 | 3/20 | 0.77 |
| ▸ | SCN2A known ✓ | Q99250 | 3/20 | 0.77 |
| ▸ | SCN3A known ✓ | Q9NY46 | 3/20 | 0.77 |
| ▸ | SCN5A known ✓ | Q14524 | 2/20 | 0.77 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.77 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.77 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.77 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.77 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.77 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.77 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.77 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.77 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.77 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.77 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.77 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.77 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.77 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.77 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Butylaminobenzoyldiethylaminoethyl SCHEMBL503019 | 0.99 | SCN1A (0.79) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL1429149 | 0.89 | LMNA (0.79) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL24370 | 0.88 | LMNA (1.00) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL1355595 | 0.88 | LMNA (1.00) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL34714 | 0.87 | LMNA (1.00) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL3176478 | 0.86 | LMNA (0.97) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL27896875 | 0.86 | LMNA (0.97) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL7774179 | 0.86 | LMNA (0.97) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL28641231 | 0.86 | LMNA (0.97) | LMNABLMKDM4EGMNNRAB9A | |
| Tetracaine SCHEMBL30333144 | 0.85 | LMNA (0.84) | LMNABLMKDM4EGMNNRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656080-B1 | DEVICE FOR DELIVERING AN ORAL CARE AGENT | RANIR LLC (US) | 2016-06-01 | — | — | EP | claimed |
| US-8956160-B2 | Device and method for delivering an oral care agent | RANIR, LLC (US) | 2015-02-17 | — | — | US | claimed |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | IHI CORPORATION (JP) | 2014-02-13 | — | — | US | claimed |
| EP-2682384-A1 | AUTO-MAGNETIC METAL SALEN COMPLEX COMPOUND | IHI Corporation (JP) | 2014-01-08 | — | — | EP | claimed |
| EP-2489329-A1 | Device and method for delivering an oral care agent | Ranir/DCP Corporation (US) | 2012-08-22 | — | — | EP | claimed |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | YOSHIHIRO ISHIKAWA (JP) | 2012-02-02 | — | — | US | claimed |
| EP-2357166-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | IHI Corporation (JP) | 2011-08-17 | — | — | EP | claimed |
| US-20090068247-A1 | BIOCOMPATIBLE DEVICES COATED WITH A TRIBONECTIN AND METHODS FOR THEIR PRODUCTION | MUCOSAL THERAPEUTICS (US) | 2009-03-12 | — | — | US | claimed |
| EP-1656080-A4 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | RANIR DCP CORP (US) | 2007-11-14 | — | — | EP | claimed |
| EP-1809200-A2 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | Ranir LLC (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2006052593-A2 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | RANIR LLC (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1656080-A2 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | Ranir/DCP Corporation (US) | 2006-05-17 | — | — | EP | claimed |
| US-20060099550-A1 | Device and method for delivering an oral care agent | RANIR/DCP CORPORATION (US) | 2006-05-11 | — | — | US | claimed |
| WO-2004004799-A2 | DEVICE AND METHOD FOR DELIVERING AN ORAL CARE AGENT | RANIR/DCP CORPORATION (US) | 2004-01-15 | — | — | WO | claimed |
| US-20040005277-A1 | Device and method for delivering an oral care agent | JPMORGAN CHASE BANK, N.A. | 2004-01-08 | — | — | US | claimed |
| US-20030175360-A1 | Symptomatic relief of gastrointestinal disorders | LUZZATTI RENZO (US) | 2003-09-18 | — | — | US | claimed |
| US-6159498-A | WATER-SOLUBLE DELIVERY DEVICE FOR APPLICATION TO MUCOSAL SURFACES | VIROTEX CORPORATION (US) | 2000-12-12 | — | — | US | claimed |
| WO-2025096900-A1 | SYNTHETIC NETWORK MATERIALS AND METHODS OF MAKING AND USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-08 | — | — | WO | disclosed |
| US-4900554-A | ACRYLIC ACID POLYMER AND CELLULOSE DERIVATIVE BLEND FOR ORAL CAVITY USE | TEIKOKU SEIYAKU CO., LTD. (JP) | 1990-02-13 | — | — | US | disclosed |
| EP-0275550-A1 | Adhesive device for application to body tissue | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | SDHB, SDHA, SLC40A1 | HRH3 1651/4885SCN1A 695/4885SCN2A 392/4885 |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | SSBP1, KCNN1, IMMT | HRH3 3267/4885SCN1A 356/4885SCN2A 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.